查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1922985

結核病市場按藥物類別、檢測類型、治療方法、最終用戶和分銷管道分類－全球預測（2026-2032 年）

Mycobacterium Tuberculosis Market by Drug Class, Test Type, Treatment Regimen, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，結核病市場價值將達到 40.8 億美元，到 2026 年將成長到 43.3 億美元，到 2032 年將達到 65.2 億美元，年複合成長率為 6.91%。

主要市場統計數據
基準年 2025 40.8億美元
預計年份：2026年 43.3億美元
預測年份：2032年 65.2億美元
複合年成長率 (%) 6.91%

本文簡要概述了構成現代結核病控制方法的臨床、診斷和公共衛生方面的內容。

由於複雜的生物學、社會和衛生系統因素，結核分枝桿菌感染仍然是全球面臨的健康挑戰。該病原體建立潛伏感染的能力、多樣化的臨床表現以及抗藥性菌株的出現（這些都使治療途徑更加複雜）持續影響臨床管理。診斷演算法和治療通訊協定正在不斷發展，以平衡敏感性、速度和可及性，而公共衛生計畫則致力於將預防、病例發現和持續護理整合到資源有限的衛生系統中。

快速診斷、治療方法創新、供應鏈韌性和以患者為中心的醫療服務如何重塑全球結核病診療管道

結核病防治格局正經歷著由技術進步、政策調整和患者照護模式演變所驅動的變革。分子診斷平台能夠提供快速檢測和抗藥性分析，從而加快診斷速度，實現早期治療性介入和更精準的治療選擇。同時，照護現場和近乎專利期的檢測技術正在推動任務轉移和去中心化，減少對中心檢查室的依賴，並擴大偏遠地區的醫療服務覆蓋範圍。

了解2025年美國關稅如何改變了結核病診斷和治療生態系統內的供應鏈、採購行為和策略性生產決策。

主要經濟體徵收進口關稅和採取貿易措施，對診斷和治療價值鏈產生連鎖反應，影響供應、籌資策略和營運成本。鑑於美國將於2025年實施關稅，診斷設備製造商、藥品經銷商和醫療系統等相關人員被迫重新評估其籌資策略和合約談判。依賴關稅進口的診斷設備、耗材和品牌治療藥物面臨到岸成本上漲的壓力，影響機構和國家層級的採購決策。

以細分市場主導的洞察，將診斷應用、治療層級趨勢、治療方法、用戶環境和分銷管道與營運重點聯繫起來。

觀點既定的市場區隔方法分析市場，可以發現診斷和治療管道存在著不同的需求和機會。在考慮藥物類別時，第一線藥物和二線藥物之間的差異仍然至關重要。第一線療法對於治療藥物敏感性疾病和維持治療方案的成功至關重要，而二線藥物則用於治療抗藥性病例，並需要加強對不利事件和療效的監測。這些趨勢會影響採購週期、庫存管理和臨床醫生培訓的重點。

區域觀點：揭示流行病學、基礎設施、政策框架和私營部門趨勢如何獨特地影響重點區域的結核病防治規劃優先事項

區域動態影響結核病防治計畫介入措施的優先順序和資源分配，各大區域的流行病學、衛生基礎設施和計畫環境均有差異。在美洲，擁有先進檢測網路的高資源都市區與集體爆發，使得有針對性的篩檢工作和具有文化敏感性的依從性策略變得尤為重要。公私部門合作以及與愛滋病防治服務的整合，對於提高病例發現率和確保全部區域醫療服務的連續性仍然至關重要。

結核病診療、治療、製造和數位健康領域的策略性公司趨勢正在推動結核病治療領域的互通性、可負擔性和夥伴關係。

診斷和製藥領域的公司策略正朝著幾個通用的主題靠攏：促進平台互通性、最佳化單次檢測和治療療程的成本，以及建立夥伴關係以加速在重點地區的市場進入。診斷公司正在投資基於試劑盒的分子診斷系統、簡化樣本製備流程以及實現結果整合到臨床工作流程中的連接性。製藥和生物技術公司正在開發伴隨診斷，以實現治療方案最佳化、安全性評估以及針對抗藥性疾病的個人化治療。

為產業領導者提供切實可行的策略行動，以加速診斷分散化、增強供應韌性、加強監管合作、推動數位整合並促進實證醫學的產生。

產業領導者應推動一系列協調一致的行動，在控制營運風險的同時提升影響力。優先推進快速分子診斷的去中心化，並確保強力的培訓和品質保證，將有助於擴大病例發現範圍，縮短患者接受適當治療的時間。同時，投資於區域製造夥伴關係和多元化的供應商網路，將增強企業應對貿易中斷和關稅造成的成本波動的能力。

以證據為導向的研究途徑：整合相關人員訪談、文獻回顧、資料三角驗證和區域地圖繪製，以確保研究結果的嚴謹性和相關性。

本分析的調查方法融合了多種定性和定量方法，旨在得出可靠且可操作的見解。主要資料收集包括對臨床專家、檢查室主任、採購負責人和衛生專案經理進行結構化訪談，以了解技術應用的操作實務和觀點。次要研究包括對同行評審文獻、臨床指南和政策文件進行系統性回顧，以闡明臨床管道和法規結構的背景。

技術進步與系統層面的準備工作相結合，迫切需要採取實際行動來縮小診斷差距、保障醫療服務並增強專案韌性。

本分析得出的LED結論指出，亟需採取實際的行動。彌合診斷差距、維持治療效果以及增強衛生系統的適應能力是改善結核病治療效果的核心。快速分子診斷和更短、更安全的治療方法為降低發病率和加速患者康復提供了切實的機會，但要充分發揮這些潛力，必須加大對人力資源開發、品管系統和供應鏈韌性的投入。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. 按藥物類別分類的結核病市場

  • 一線藥物
  • 二線藥物

9. 按檢測類型分類的結核病市場

  • 培養試驗
  • 干擾素γ釋放試驗
  • 顯微鏡
  • 分子檢測
    • LAMP方法
    • PCR
    • Xpert Mtb Rif
  • 皮膚測試

10. 按治療方法的結核病市場

  • 抗藥性治療
    • 廣域電阻
    • 多重抗藥性
  • 藥物敏感性治療

第11章 依最終用戶分類的結核病市場

  • 診所
  • 醫院
  • 檢查機構
  • 研究所

第12章 結核病市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 各地區結核病市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 結核病市場（依群體分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國結核病市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國結核病市場

第17章：中國的結核病市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Molecular Inc.
  • Actiza Pharmaceutical Private Limited
  • Anuh Pharma Ltd.
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Cadila Healthcare Ltd.
  • CapitalBio
  • Care Formulation Labs Private Limited
  • Cepheid, Inc.
  • Cipla Ltd.
  • DaAN Gene Company
  • Eiken Chemical Co., Ltd.
  • GlaxoSmithKline plc
  • Hain Lifescience GmbH
  • Hetero Labs Ltd.
  • Hologic, Inc.
  • Johnson & Johnson
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Molbio Diagnostics Private Limited
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • QIAGEN NV
  • Roche Diagnostics International AG
  • Sandoz International GmbH
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Thermo Fisher Scientific Inc.
  • Titan BIoTech Limited
  • Viatris Inc.
Product Code: MRR-867BED9A9EA2

The Mycobacterium Tuberculosis Market was valued at USD 4.08 billion in 2025 and is projected to grow to USD 4.33 billion in 2026, with a CAGR of 6.91%, reaching USD 6.52 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.08 billion
Estimated Year [2026] USD 4.33 billion
Forecast Year [2032] USD 6.52 billion
CAGR (%) 6.91%

A concise orientation to the clinical, diagnostic, and public health dimensions that define contemporary approaches to Mycobacterium tuberculosis management

Mycobacterium tuberculosis remains a persistent global health challenge driven by complex biological, social, and health system factors. Clinical management continues to be shaped by the pathogen's ability to establish latent infection, variable clinical presentations, and the growing prevalence of drug-resistant strains that complicate therapeutic pathways. Diagnostic algorithms and treatment protocols have evolved to balance sensitivity, speed, and accessibility, while public health programs strive to integrate prevention, case-finding, and continuity of care into constrained health systems.

Contemporary attention focuses on closing diagnostic gaps, shortening treatment duration, and preserving the efficacy of existing antimicrobials. Advances in molecular diagnostics and digital health platforms have introduced new opportunities to decentralize testing and accelerate clinical decision-making, yet barriers remain around cost, supply chain resilience, and workforce capacity. Concurrently, treatment innovation has delivered new regimens and drug combinations that improve outcomes for resistant disease, but equitable access and adherence support are required to translate efficacy into population-level impact.

As stakeholders across clinical, laboratory, policy, and commercial domains align priorities, coordinated strategies that emphasize diagnostics-treatment integration, strengthened surveillance for resistance, and targeted investment in underserved settings will be essential to make measurable progress. This introduction outlines the biological context, current practice contours, and the strategic inflection points shaping how healthcare systems and industry partners respond to tuberculosis today.

How rapid diagnostics, therapeutic innovation, supply chain resilience, and patient-centered delivery are reshaping tuberculosis care pathways globally

The landscape of tuberculosis control is experiencing transformative shifts driven by technological progress, policy recalibration, and evolving patient care models. Molecular diagnostic platforms that offer rapid detection and resistance profiling have accelerated diagnostic turnaround, enabling earlier therapeutic intervention and more precise treatment selection. At the same time, point-of-care and near-patient testing technologies are enabling task shifting and decentralization, which reduces dependence on central laboratories and expands access in peripheral settings.

Therapeutic innovation has introduced novel agents and shorter regimens that are redefining treatment paradigms for drug-resistant disease. These advances interact with strengthened antimicrobial stewardship frameworks and more granular resistance surveillance to inform regimen selection and preserve drug efficacy. Parallel developments in digital health-such as electronic adherence monitoring, telehealth-enabled consultations, and integrated case management systems-are enhancing continuity of care and creating data streams that support programmatic decision-making.

Supply chain resilience and strategic manufacturing investments have become priorities in response to geopolitical shifts and procurement volatility, prompting stakeholders to diversify sourcing and develop regional capacity. Meanwhile, increased emphasis on patient-centered models and social determinants of health is reshaping service delivery, recognizing that diagnostics and therapeutics must be coupled with adherence support, nutritional assistance, and socioeconomic interventions to realize durable outcomes.

Understanding how United States tariff measures initiated in 2025 have altered supply chains, procurement behaviors, and strategic manufacturing decisions within tuberculosis diagnostics and therapeutics ecosystems

The introduction of import tariffs and trade measures by major economies can reverberate across diagnostic and therapeutic value chains, affecting availability, procurement strategies, and operational costs. In the context of tariffs implemented by the United States in 2025, stakeholders across diagnostics manufacturers, pharmaceutical distributors, and health systems have had to reassess sourcing strategies and contract negotiations. Equipment-dependent diagnostics, consumables, and branded therapeutics exposed to tariffed imports face upward pressure on landed costs, which in turn influences purchasing decisions at institutional and national levels.

Consequently, procurement agencies and manufacturers have pursued a mix of mitigation strategies, including nearshoring production, qualifying alternative suppliers, and accelerating regional manufacturing partnerships to reduce exposure to tariff-related volatility. For some health programs, these adjustments have introduced delays in onboarding new technologies or replenishing stock, particularly where regulatory approvals and quality assurance processes are localized. At the same time, tariff-driven cost pressures have incentivized suppliers to optimize product design for lower-cost consumables and to explore bundled service agreements that smooth procurement cycles.

Moving forward, the interplay between trade policy and public health highlights the importance of diversified supplier networks, collaborative procurement mechanisms, and forward-looking contracting that anticipates policy shifts. For clinical programs, maintaining continuity of high-quality diagnostics and treatment supplies requires active engagement with procurement experts, investment in local manufacturing where feasible, and adaptive inventory management to buffer against episodic supply disruptions.

Segment-driven insights that link diagnostic modality adoption, therapeutic class dynamics, treatment regimens, user settings, and distribution channels to operational priorities

Examining the market through established segmentation lenses reveals differentiated needs and opportunities across diagnostic and treatment pathways. When considering drug class categories, the distinction between first-line and second-line agents remains pivotal: first-line therapies are central to treating drug-susceptible disease and sustaining programmatic success, while second-line drugs drive clinical strategies for resistant cases and require enhanced monitoring for adverse events and efficacy. These dynamics influence procurement cycles, stock management, and clinician training priorities.

Test type segmentation underscores the coexistence of legacy and emerging diagnostic modalities. Culture-based assays and microscopy retain roles in clinical confirmation and resource-limited settings, while interferon gamma release assays and skin testing occupy niche roles in latent infection screening. Molecular tests, encompassing loop-mediated isothermal amplification, polymerase chain reaction platforms, and cartridge-based assays that detect both pathogen presence and rifampicin resistance, are increasingly central to rapid case detection and appropriate regimen initiation. The distribution of testing modalities across clinical pathways dictates laboratory investment, personnel upskilling, and quality assurance frameworks.

Treatment regimen segmentation differentiates strategies for drug-susceptible and drug-resistant disease, with multidrug-resistant and extensively drug-resistant categories requiring specialized therapeutic oversight and often prolonged care coordination. End user segmentation-spanning clinics, hospitals, laboratories, and research institutes-reflects varied capabilities, utilization patterns, and procurement authorities, which in turn shape demand for point-of-care versus centralized solutions. Distribution channel segmentation, covering hospital pharmacies, online pharmacies, and retail pharmacies, highlights evolving access models and underscores the need for regulatory clarity, inventory traceability, and patient counseling across diverse points of dispensation.

Together, these segmentation perspectives inform where investments in diagnostics, therapeutics, training, and supply chain improvements will yield the greatest operational and clinical returns. The intersection of molecular testing capacity with empowered end users and adaptive distribution channels presents the most immediate opportunity to reduce diagnostic delay and improve linkage to appropriate regimens.

Regional perspectives that reveal how epidemiology, infrastructure, policy frameworks, and private sector dynamics uniquely shape tuberculosis program priorities across major geographies

Regional dynamics shape how tuberculosis programs prioritize interventions and allocate resources, with distinct epidemiology, health infrastructure, and policy environments across major geographies. In the Americas, heterogeneity is pronounced between high-resource urban centers with advanced laboratory networks and lower-resource or remote communities that experience barriers to access. Migratory flows and concentrated outbreaks in vulnerable populations necessitate targeted screening initiatives and culturally tailored adherence strategies. Public-private engagement and integration with HIV services remain central to improving case detection and continuity of care across the region.

The Europe, Middle East & Africa constellation encompasses a broad range of settings from advanced public health systems to fragile states where conflict and displacement complicate service delivery. In parts of Africa, high burden and limited laboratory capacity create urgent need for decentralized molecular diagnostics and strengthened supply chains. Meanwhile, countries in Europe and the Middle East focus on surveillance for imported resistance, sustaining treatment adherence among diverse populations, and aligning regulatory pathways to expedite access to newer therapeutics.

Asia-Pacific carries the largest absolute clinical burden and demonstrates rapid uptake of new diagnostics and treatment approaches in several large health systems. National programs in high-burden countries are innovating with public-private mix models, leveraging digital adherence tools, and scaling molecular testing while contending with complex market dynamics in the private sector. Regional manufacturing hubs and active clinical research networks also create opportunities for localized production and evidence generation, which can shorten the translation period between trial results and policy adoption.

Strategic corporate moves across diagnostics, therapeutics, manufacturing, and digital health that are driving interoperability, affordability, and partnerships in tuberculosis care

Corporate strategies across diagnostics and pharmaceutical segments have converged on a few consistent themes: advancing platform interoperability, optimizing cost per test or treatment course, and forging partnerships that accelerate market access in priority settings. Diagnostics firms are investing in cartridge-based molecular systems, simplified sample preparation, and connectivity features that integrate results into clinical workflows. Pharmaceutical manufacturers and biotech players are pursuing regimen optimization, safety profiling, and companion diagnostics that enable personalized approaches for resistant disease.

Collaboration between diagnostic vendors and drug developers is increasingly common, motivated by the need to align rapid resistance detection with timely therapeutic decisions. Contract manufacturing organizations and regional producers have become strategic partners for multinational firms seeking to mitigate supply chain risk and improve lead times. Meanwhile, companies offering digital health solutions and adherence technologies are positioning their products as complementary to diagnostics and therapeutics, emphasizing outcomes-based value propositions to payers and programs.

Competitive dynamics also include pricing pressure from procurers and reimbursement agencies, which drives a focus on cost-effectiveness and long-term total cost of care. Investment in post-market evidence generation, real-world effectiveness studies, and implementation research supports product adoption and informs clinical guidelines. Overall, corporate actions are converging on scalable, integrated solutions that reduce diagnostic delay, simplify treatment delivery, and improve traceability across distribution channels.

Practical, strategic actions for industry leaders to accelerate diagnostic decentralization, supply resilience, regulatory collaboration, digital integration, and evidence generation

Industry leaders must pursue a set of coordinated actions to advance impact while managing operational risk. Prioritizing decentralization of rapid molecular diagnostics and ensuring robust training and quality-assurance frameworks will expand case detection and reduce time to appropriate therapy. Simultaneously, investing in regional manufacturing partnerships and diversified supplier networks will strengthen resilience against trade disruptions and tariff-driven cost volatility.

Strengthening collaborations with national programs and regulatory authorities can streamline approval pathways and enable adaptive procurement models that respond to epidemiological shifts. Leaders should integrate digital health tools that support adherence, outcome monitoring, and data-driven program management, thereby creating closed-loop systems that link diagnosis to sustained treatment completion. Pricing strategies must balance affordability and sustainability, with tiered approaches and outcome-based contracting explored where feasible.

Finally, committing to implementation research and real-world evidence generation will accelerate policy adoption and inform iterative improvements in product design and service delivery. Cross-sector partnerships that include civil society, patient advocacy groups, and payers will be essential to design equitable access programs and to ensure that innovations translate into population-level reductions in morbidity and mortality.

An evidence-driven research approach integrating stakeholder interviews, literature synthesis, data triangulation, and regional mapping to ensure rigor and relevance in insights

The research methodology underpinning this analysis integrates multiple qualitative and quantitative approaches to ensure robust, actionable findings. Primary data collection included structured interviews with clinical experts, laboratory directors, procurement officers, and health program managers to capture operational realities and perspectives on technology adoption. Secondary research involved systematic review of peer-reviewed literature, clinical guidelines, and policy documents to contextualize clinical pathways and regulatory frameworks.

Data triangulation techniques were applied to reconcile differences across sources, while thematic analysis identified recurring barriers and enablers related to diagnostics, treatment regimens, and distribution. Segmentation schemas were mapped to end-user capabilities and procurement modalities to surface targeted insights for stakeholders operating at clinic, hospital, laboratory, and research institute levels. Regional analyses accounted for epidemiologic patterns, infrastructure maturity, and policy environments to ensure relevance across diverse settings.

Quality assurance measures included cross-validation of interview findings with documented program reports and iterative peer review by subject-matter experts. Ethical considerations were observed in primary engagements, ensuring confidentiality and informed consent. The result is an evidence-informed synthesis that emphasizes operational feasibility, adoption barriers, and strategic levers for improving tuberculosis detection and treatment pathways.

Converging technological advances and system-level preparedness create a practical imperative to close diagnostic gaps, protect therapeutics, and strengthen program resilience

The conclusions drawn from this analysis underscore an urgent yet actionable agenda: closing diagnostic gaps, preserving therapeutic efficacy, and strengthening health system adaptability are central to improving tuberculosis outcomes. Rapid molecular diagnostics and shorter, safer treatment regimens offer tangible opportunities to reduce morbidity and accelerate patient recovery, but realizing their potential requires coordinated investments in workforce capacity, quality systems, and supply chain resilience.

Trade policy shifts and procurement volatility underscore the need for diversified sourcing and regional manufacturing partnerships to sustain access to essential diagnostics and medicines. Equally important is the integration of clinical services with digital tools that support adherence and enable real-time surveillance for resistance patterns. Collective action across private industry, public health authorities, and civil society will be necessary to translate technological advances into equitable access and measurable public health gains.

In sum, the evolving tuberculosis landscape presents both challenges and opportunities: by aligning innovation with pragmatic implementation strategies, stakeholders can converge on solutions that improve detection, optimize treatment, and strengthen long-term resilience of TB programs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Mycobacterium Tuberculosis Market, by Drug Class

  • 8.1. First Line Drugs
  • 8.2. Second Line Drugs

9. Mycobacterium Tuberculosis Market, by Test Type

  • 9.1. Culture Tests
  • 9.2. Interferon Gamma Release Assays
  • 9.3. Microscopy Tests
  • 9.4. Molecular Tests
    • 9.4.1. Lamp
    • 9.4.2. Pcr
    • 9.4.3. Xpert Mtb Rif
  • 9.5. Skin Tests

10. Mycobacterium Tuberculosis Market, by Treatment Regimen

  • 10.1. Drug Resistant Treatment
    • 10.1.1. Extensively Drug Resistant
    • 10.1.2. Multidrug Resistant
  • 10.2. Drug Susceptible Treatment

11. Mycobacterium Tuberculosis Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals
  • 11.3. Laboratories
  • 11.4. Research Institutes

12. Mycobacterium Tuberculosis Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Mycobacterium Tuberculosis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Mycobacterium Tuberculosis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Mycobacterium Tuberculosis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Mycobacterium Tuberculosis Market

17. China Mycobacterium Tuberculosis Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Molecular Inc.
  • 18.6. Actiza Pharmaceutical Private Limited
  • 18.7. Anuh Pharma Ltd.
  • 18.8. AstraZeneca PLC
  • 18.9. Bayer AG
  • 18.10. Becton, Dickinson and Company
  • 18.11. bioMerieux SA
  • 18.12. Cadila Healthcare Ltd.
  • 18.13. CapitalBio
  • 18.14. Care Formulation Labs Private Limited
  • 18.15. Cepheid, Inc.
  • 18.16. Cipla Ltd.
  • 18.17. DaAN Gene Company
  • 18.18. Eiken Chemical Co., Ltd.
  • 18.19. GlaxoSmithKline plc
  • 18.20. Hain Lifescience GmbH
  • 18.21. Hetero Labs Ltd.
  • 18.22. Hologic, Inc.
  • 18.23. Johnson & Johnson
  • 18.24. Lupin Limited
  • 18.25. Macleods Pharmaceuticals Ltd.
  • 18.26. Merck & Co., Inc.
  • 18.27. Molbio Diagnostics Private Limited
  • 18.28. Novartis AG
  • 18.29. Otsuka Pharmaceutical Co., Ltd.
  • 18.30. Pfizer Inc.
  • 18.31. QIAGEN N.V.
  • 18.32. Roche Diagnostics International AG
  • 18.33. Sandoz International GmbH
  • 18.34. Sanofi S.A.
  • 18.35. Serum Institute of India Pvt. Ltd.
  • 18.36. Thermo Fisher Scientific Inc.
  • 18.37. Titan Biotech Limited
  • 18.38. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY FIRST LINE DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY FIRST LINE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY FIRST LINE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SECOND LINE DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SECOND LINE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SECOND LINE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY CULTURE TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY CULTURE TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY CULTURE TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MICROSCOPY TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MICROSCOPY TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MICROSCOPY TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY LAMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY LAMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY LAMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY XPERT MTB RIF, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY XPERT MTB RIF, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY XPERT MTB RIF, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SKIN TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SKIN TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SKIN TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY EXTENSIVELY DRUG RESISTANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY EXTENSIVELY DRUG RESISTANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY EXTENSIVELY DRUG RESISTANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MULTIDRUG RESISTANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MULTIDRUG RESISTANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MULTIDRUG RESISTANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG SUSCEPTIBLE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG SUSCEPTIBLE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG SUSCEPTIBLE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 150. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 151. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 152. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 174. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 175. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 176. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 182. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 183. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 184. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)